From: Quality of life in children suffering from headaches: a systematic literature review
Author | Year | Country | Type of headache | Diagnosic criteria | Gender (%) Female-male | Age range (in years) | Sample size | Comparison sample | QoL questionnaire used | Patient-, parent or both reported | Exclusion psychiatric comorbidities |
---|---|---|---|---|---|---|---|---|---|---|---|
Al-Hashel [21] | 2020 | Kuwait | PH | ICHD-III crit | 69–31 | 7 to 17 | 466 | N/A | HARDSHIP | Patient | No |
Açıkel [22] | 2021 | Turkey | TTH, M | ICHD-II | 42–58 | 8 to 18 | 59 | Normative sample | HARDSHIP | Patient | Yes |
Amouroux [23] | 2017 | France | M, TTH | ICHD-II crit | 43–58 | 4 to 18 | 73 | N/A | VSP-A | Patient | No |
Bai [24] | 2017 | Netherlands | M, SH | Parent reported | 57–43 | 4 to 11 | 77 | Normative sample, asthma, eczema, ADHD, dyslexia | CHQ-PF28 | Parent | Yes |
Benore [25] | 2018 | USA | CM, cTTH, daily headache | ICHD-II crit | 74–26 | up to 18 | 135 | N/A | PedsQL | Both | No |
Bruijn [26] | 2009 | Netherlands | M, cTTH | IHS class | NR | 4 to 17 | 70 | Normative sample, ADHD, asthma | CHQ-PF50 | Parent | No |
Caruso [27] | 2022 | USA | M, UdH | ICHD-III, or clinician-reported | 76–24 | 10 to 17 | 88 | N/A | PedsQL | Patient | No |
Castro [12] | 2013 | Brazil | M, cDH, cTTH, eTTH | Episode > 3 months | 61–40 | 7 to 14 | 185 | Normative sample | PedsQL | Patient | No |
Chen [28] | 2007 | Japan | NR | Episode > 6 months | NR | 5 to 18 | 85 | Normative sample | PedsQL | Both | Yes |
Connelly [29] | 2006 | USA | M, CDH, eTTH | Neurologist | NR | 7 to 12 | 40 | Normative sample | PedsQL | Both | Yes |
Cordova [30]b | 2021 | Germany | RH | Self-reported | 37–63 | 11 to 17 | 2238 | Normative sample | KINDL | Both | No |
Gozubatik [31] | 2021 | Turkey | TTH, M | ICHD-III crit | 39–61 | 8 to 18 | 61 | Normative sample | PedsQL | Patient | Yes |
De Tommaso [32] | 2017 | Italy | M | ICHD-III crit | 56–44 | 8 to 15 | 151 | N/A | PedsQL | Both | No |
Dudeney [33] | 2019 | USA | cH | 24 > episodes < 3 months | 71–29 | 10 to 18 | 56 | N/A | PedsQL-SF | Patient | No |
Eren [34] | 2021 | Turkey | M | IHS class | 65–35 | 8 to 18 | 43 | Normative sample | PedsQL | Parent | Yes |
Ferracini [35] | 2013 | Brazil | M | IHS class | NR | 6 to 12 | 50 | Normative sample | PedsQL | Both | No |
Genc [36] | 2021 | Lithuania | M, TTH, pMOH, headache ≥ 15 days | Self-reported, ICHD-III crit | - | 7 to 17 | 1858 | Normative sample | HARDSHIP | Patient | No |
Genizi [37] | 2019 | Israel | M | ICHD-III crit | 59–41 | 8 to 12 | 54 | Normative sample | PedsQL | Patient | No |
Gerber [38] | 2010 | Germany | M, TTH | IHS class | 65–35 | 7 to 16 | 34 | N/A | KINDL | Both | No |
Hainsworth [39] | 2014 | USA | M, CDH | Episode > 3 months | 43–57 | 11 to 16 | 7 | N/A | PedsQL | Both | No |
Hao [40] | 2010 | China | M | Clinician-reported | 50–50 | 5 to 18 | 618 | Normative sample, leukemia, epilepsy, Gilles de la Tourette's syndrome | PedsQL | Both | No |
Hesse [41] | 2015 | USA | RH | ≥ 4 episodes/month for ≥ 3 months | 100 (F) | 11 to 16 | 15 | N/A | PedsQL | Both | Yes |
Kashikar-Zuck [42] | 2013 | USA | cM | ICHD-II crit | 82–18 | 10 to 18 | 153 | Juvenile fibromyalgia | PedsQL | Both | No |
Kernick [43] | 2009 | UK | NR | Self-reported | NR | 12 to 15 | 648 | Normative sample | PedsQL, PedMIDAS | Patient | No |
Koenig [44] | 2013 | Germany | M, CM, eTTH, cTTH | ICHD-II crit | 78–22 | 12 to 17 | 71 | N/A | KIDSCREEN-27 | Patient | Yes |
Kovacevic [45] | 2017 | Serbia | M | ICHD-III crit | 53–47 | 7 to 17 | 32 | N/A | KIDSCREEN-27 | Both | Yes |
Koller [46] | 2019 | Austria | M | ICHD-III crit | 49–51 | 8 to 17 | 37 | Normative sample | PedsQL | Patient | No |
Krause [47] | 2016 | Germany | NR | Self-reported | NR | 3 to 17 | 10.667 | Normative sample | KIDSCREEN-10 | Patient | No |
Ladner [48] | 2016 | USA | NR | NR | NR | 5 to 18 | 67 | Normative sample | CHIP, HUI3 | Both | No |
Langeveld [49] | 1999 | The Netherlands | M | Clinician-reported | 60–40 | 12 to 18 | 64 | Normative sample | QLH-Y | Patient | No |
Long [50] | 2007 | USA | M, TTH or Combined | NR | NR | 8 to 10 | 44 | Sickle cell disease, juvenile idiopathic arthritis | CHQ-PF50 | Parent | No |
Massey [51] | 2008 | Netherlands | NR | Self-reported | 47–53 | 12 to 18 | 685 | Normative sample | PedsQL-SF | Patient | No |
McDonald [8] | 2011 | USA | M | ICHD-II crit | 59–41 | 12 to 17 | 531 | N/A | MSQ-A | Patient | No |
Milde-Busch [52] | 2010 | Germany | M, TTH | IHS class | 61–39 | 13 to 17 | 475 | Normative sample | KINDL | Patient | No |
Nodari [53] | 2002 | Italy | M, TTH | NR | 55–45 | 10 to 18 | 310 | Normative sample | QLH-Y | Patient | No |
Orr [54] | 2017 | Canada | M | ICHD-II crit | 68–32 | 10 to 18 | 85 | Normative sample | PedsQL | Patient | Yes |
Öztop [55] | 2016 | Turkey | M | IHS class | 74–26 | 9 to 16 | 35 | Normative sample | PedsQL | Both | No |
Palermo [56] | 2005 | USA | M, TTH | NR | NR | 13 to 16 | 45 | Sickle cell disease, juvenile idiopathic arthritis | CHQ-CF87 | Patient | No |
Paniccia [57] | 2020 | Canada | UdH, M | NR | NR | 8 to 12 | 231 | Normative sample | KIDSCREEN-10 Index | NR | No |
Petersen [58] | 2009 | Sweden | NR | Self-reported | NR | 8 to 14 | 769 | Normative sample | PedsQL | Both | No |
Philipp [59] | 2019 | Austria | M, TTH, pMOH, UdH, headache ≥ 15 days/month | ICHD-III crit | 60–40 | 10 to 18 | 2563 | Normative sample | KIDSCREEN-10, -52 and -27 | NR | No |
Powers [60] | 2003 | USA | M, CDH | IHS class | 55–45 | 2 to 18 | 572 | Normative sample, cancer, rheumatologic disease | PedsQL | Both | No |
Powers [61] | 2004 | USA | M | IHS class | 57–43 | 2 to 18 | 686 | Normative sample | PedsQL | Both | No |
Rapoff [62] | 2014 | USA | M | ICHD-II crit | 71–29 | 7 to 12 | 35 | N/A | PedsQL | Both | Yes |
Rettig [63] | 2021 | USA | CM | Treatment was indicated | 21–79 | 10 to 17 | 135 | N/A | PedsQL | NR | No |
Riatha [64] | 2013 | Indonesia | PH | ICHD-II crit | 60–40 | 13 to 17 | 75 | Normative sample | PedsQL | Patient | No |
Rocha-Filho [65] | 2014 | Brazil | PM, M, TTH, UdH | Clinician-reported | NR | 10 to 15 | NR | N/A | PedsQL | Patient | No |
Sciruicchio [66] | 2019 | Italy | M, cM | ICHD-II crit | 60–41 | 8 to 17 | 190 | N/A | PedsQL | Both | Yes |
Seeger [67] | 2014 | Canada | PTH | NR | 67–33 | 13 to 17 | 15 | N/A | PedsQL | Patient | No |
Şentürk [68] | 2022 | Turkey | M, TTH, or both | ICHD-III crit | 69–31 | 8 to 18 | 80 | N/A | PedsQL | NR | No |
Shaygan [69] | 2021 | Iran | cH | ICD-II crit | NR | 12 to 18 | NR | Musculoskeletal pain, other chronic pain | PedsQL | Patient | Yes |
Shiri [70] | 2013 | Israel | M, cTTH | ICHD-II crit | 30–70 | 10 to 18 | 10 | N/A | PedsQL | Patient | Yes |
Slater [71] | 2012 | USA | cDH | ICHD-II crit | 78–22 | 10 to 17 | 169 | N/A | PedsQL | Both | No |
Talarska [72] | 2017 | Poland | M, CH, TTH | IHD-2004 | 59–41 | 8 to 18 | 173 | Normative sample, epilepsy | PedsQL | Both | Yes |
Talarska [73] | 2007 | Poland | M, TTH | NR | NR | 8 to 18 | 64 | N/A | PedsQL | Both | No |
Todorov [74] | 2009 | USA | M | IHS class | 75–25 | 11 to 17 | 63 | Normative sample | PedsQL, PedMIDAS, MSQ-A | Both | Yes |
Uneri [75] | 2009 | Turkey | M | ICHD-II crit | 80–20 | 13 to 18 | 30 | Normative sample | PedsQL | Both | Yes |
Ung [76] | 2018 | USA | NR | NR | NR | 7 to 17 | 84 | N/A | PedsQL | Both | No |
Witt [77] | 2009 | Germany | NR | NR | 55–45 | 7 to 16 | 67 | N/A | KINDL | Patient | No |
Wober-Bingol [78] | 2014 | Austria, Turkey | M, MOH, TTH | ICHD-II crit | 52–48 | 6 to 17 | 1.073 | N/A | HARDSHIP | Patient | No |
Yaghini [79] | 2022 | Iran | M | IHS class | 36–64 | 5 to 15 | 72 | N/A | PedMIDAS | Patient | No |